SUBSCRIBE
SUBSCRIBE
Gail Dutton

Gail Dutton

Freelance writer

Gail Dutton is a veteran biopharmaceutical reporter, covering the industry from Washington state. You can contact her at gaildutton@gmail.com and see more of her work on Muckrack.

Programmed death ligand 1 is being said to be help
Genetic Link to Obesity Could Expedite End to Global Epidemic
Obesity is implicated in multiple diseases that send health care costs skyrocketing. It’s not just a problem for the U.S. or Western society, either. Obesity is a global epidemic affecting adults and children alike.
August 13, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Can COVID-19 be Eradicated? New Zealand Researchers Say “Yes”
COVID-19 probably can be eradicated globally, just like polio, according to research just published in BMJ Global Health. That assumes, however, that a high rate of vaccination occurs globally and that there is a quick response to emerging variants.
August 12, 2021
 · 
4 min read
 · 
Gail Dutton
Tasos Katopodis/Getty Images
Policy
Emergent’s Woes Are Dire but Not Insurmountable, Legal Expert Says
Emergent BioSolutions has approval to resume manufacturing vaccines, but its lawsuit issues haven’t gone away as easily.
August 11, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Ovoca Bio’s “Female Viagra” Nasal Spray Inching Closer to Market
Called “female Viagra” in the media, Ovoca Bio’s BP-101 (Libicore) nasal spray therapy for low libidos in premenopausal women is undergoing Phase II trials.
August 9, 2021
 · 
4 min read
 · 
Gail Dutton
RNA Therapeutics Experience Renaissance Amidst Global Pandemic
RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins.
August 5, 2021
 · 
3 min read
 · 
Gail Dutton
Ophthalmology Companies See Global Opportunities for Next-Gen, Non-Invasive Therapies
Ophthalmology has become a focal point for private equity and venture capitalists in the past 18 months, despite being a small niche in the biopharmaceutical space.
August 2, 2021
 · 
5 min read
 · 
Gail Dutton
Drug Development
Annovis Bio’s AD/PD Therapy Reduces Cytotoxic Cascade in Phase IIa Trials
Annovis Bio’s therapy for Alzheimer’s disease is fast-acting and has the potential for Alzheimer’s patients to significantly improve cognition and motor function, according to data presented at the Alzheimer’s Association International Conference® 2021 (AAIC®), held July 26th through 30th.
July 29, 2021
 · 
3 min read
 · 
Gail Dutton
Drug Development
Emerging Drug-Resistant Fungi Threat Offset by Cidara’s Phase III Antifungal Therapy
The FDA Watch List considers drug-resistant Candida auris (C. auris) an urgent threat, drug-resistant Candida species a serious threat, and azole-resistant Aspergillus Fumigatus worth watching – especially since person-to-person transmission of drug-resistant fungi has been recently documented.
July 28, 2021
 · 
4 min read
 · 
Gail Dutton
Bryan Dechairo, newly appointed president and CEO
Business
Sherlock Biosciences’ CEO: “It’s Better to Be Disruptive Than to Follow the Crowd”
Bryan Dechairo, newly appointed president and CEO of Sherlock Biosciences, learned early to fill gaps and seize opportunities. Read more about his views.
July 26, 2021
 · 
4 min read
 · 
Gail Dutton
BioForest
Unmasking the SARS-CoV-2 Delta Variant: What We Know So Far
Just as it was beginning to appear safe to return to maskless, pre-pandemic life, the Delta variant of the SARS-CoV-2 virus emerged. It is fast-spreading, more likely to lead to hospitalizations, and accounts for most of the breakout infections among fully vaccinated individuals.
July 26, 2021
 · 
4 min read
 · 
Gail Dutton
Craig Rayner / Certara President, Integrated Drug
Business
Africa is the Next Frontier for Biosimulation, as Certara Trains Up Talent
Biosimulation is integral to drug development today, with fierce competition for expert scientists to run the simulations and interpret the results. Craig Rayner, president of Certara, a biosimulation company, is turning to Africa to unlock an untapped reservoir of talent.
July 22, 2021
 · 
4 min read
 · 
Gail Dutton
Yochi Slonim / Anima Biotech CEO
Business
Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says
“When big pharma collaborates with biopharma companies, the main risk isn’t the technology, but the commitment of the partner,” according to serial entrepreneur Yochi Slonim, CEO of Anima Biotech. That isn’t merely his opinion. The question arises in partnering meetings routinely.
July 22, 2021
 · 
5 min read
 · 
Gail Dutton
Drug Development
Equity vs. Public Health Drives Thinking on COVID-19 Vaccine Booster Shots
American health authorities have a dilemma. On one hand, COVID-19 booster shots for immunocompromised patients dramatically increase their immune response. On the other, in many parts of the world only a tiny fraction of the population have received even one dose of any COVID-19 vaccine. So, who should get the vaccines?
July 20, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Meissa’s Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates
Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.
July 19, 2021
 · 
4 min read
 · 
Gail Dutton
Drug Development
Genetically Modifying Bats Could Prevent the Next Pandemic, Scientists Say
The next COVID pandemic could be prevented by using a gene drive to preemptively edit the genome of bats to prevent them from becoming hosts for coronaviruses, according to a proposal by scientists from Israel’s Interdisciplinary Center Herzelia and the National Institutes of Health.
July 15, 2021
 · 
6 min read
 · 
Gail Dutton
Load More